Neuronascent Granted Third US Patent for Potential Methods to Treat Alzheimer’s, Other Disorders

Neuronascent Granted Third US Patent for Potential Methods to Treat Alzheimer’s, Other Disorders
Neuronascent has been issued a U.S. patent for methods of stimulating neurogenesis and/or inhibiting neuronal degeneration that have potential therapeutic applications in Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, and other psychiatric disorders. The biopharma Neuronascent discovers and develops novel therapeutics aimed at halting or reversing neurological disorders. The new patent (No. 9,539,261) expands the company's scope of patent protection to several new groups of compounds that could potentially improve treatments for patients suffering from neurodegenerative and neuropsychiatric disorders. Patients of Alzheimer’s disease often lose their ability to learn, remember, reason or make decisions, as do patients of traumatic brain injury and many diseases that cause neuronal loss. According to Neuronascent, neurogenesis could be used to treat Alzheimer’s if nascent neurons can survive long enough to produce functional neurons. This means there is a need for a neurogenic agent that promotes the proliferation of a neuronal precursor and that causes the differentiation and survival of the neurons. The patent follows effectiveness and safety studies, which are required before any human testing is approved. "We are pleased with the expansion of patent protection for our small-molecule agents aimed at improving the lives of patients and their caregivers, especially those affected by cogniti
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *